Meridian wins Cambridge Biotech enteric product line
This article was originally published in Clinica
Meridian Diagnostics (US) is to buy Cambridge Biotech's enteric product line for $5.5 million cash. The deal replaces an agreement formed with Carter-Wallace in May for the purchase of the products for $4.5 million cash (see Clinica No 705, p 1). Cambridge Biotech was instructed by the bankruptcy court to open the offer to bidding.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.